Medication Overview

Need new introductory text here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula. 

Action items for Medication Overview

Visit these 3 links for in-depth information and articles

Action item one

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula. 

Action item two

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula. 

Action item three

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula. 

FEATURE

TBD - will add after article migration

ADDITIONAL READING

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with